Literature DB >> 21272745

Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy.

Rutger J Van Bommel1, Sjoerd A Mollema, C Jan Willem Borleffs, Matteo Bertini, Claudia Ypenburg, Nina Ajmone Marsan, Victoria Delgado, Ernst E Van Der Wall, Martin J Schalij, Jeroen J Bax.   

Abstract

OBJECTIVES: Aims of this study were to investigate the effect of renal function on left ventricular (LV) reverse remodeling and long-term outcome after cardiac resynchronization therapy (CRT), and to explore the relation between LV reverse remodeling and changes in renal function at 6-month follow-up.
BACKGROUND: Renal insufficiency is highly prevalent in heart failure patients, including patients eligible for CRT, and is associated with poor prognosis.
METHODS: The study comprised 490 patients undergoing CRT. Response to CRT was defined as a decrease in LV end-systolic volume ≥15% at 6-month follow-up. Primary end point during long-term follow-up was all-cause mortality.
RESULTS: At baseline, mean estimated glomerular filtration rate (eGFR) was 70 ± 28 ml/min/1.73 m². At 6-month follow-up, 263 patients (54%) demonstrated response to CRT. Responders had an eGFR of 74 ± 26 ml/min/1.73 m² versus 64 ± 28 ml/min/1.73 m² in nonresponders (p < 0.001). During long-term follow-up, patients with an eGFR <60 ml/min/1.73 m² had higher mortality than patients with an eGFR of 60 to 90 ml/min/1.73 m² or an eGFR >90 ml/min/1.73 m² (p < 0.001). Finally, responders to CRT had preservation of renal function (ΔeGFR -0.6), whereas nonresponders had a slight worsening in renal function (ΔeGFR -4.7, p < 0.05).
CONCLUSIONS: Impaired renal function in CRT candidates is associated with nonresponse during 6-month follow-up. Additionally, patients with impaired renal function have worse long-term survival after CRT. Response to CRT results in preservation of renal function. Copyright Â
© 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21272745     DOI: 10.1016/j.jacc.2010.06.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

1.  Cardiorenal Resynchronization Therapy: Strengthening the Heart and Kidneys.

Authors:  Edmond K Obeng-Gyimah; Rajat Deo
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

2.  Cardiac Resynchronization Therapy in CKD Stage 4 Patients.

Authors:  Ulas Höke; Mand J H Khidir; Enno T van der Velde; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

3.  A patient with heart failure and worsening kidney function.

Authors:  Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 4.  The role of the kidney in acute and chronic heart failure.

Authors:  Gaetano Ruocco; Alberto Palazzuoli; Jozine M Ter Maaten
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

5.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

6.  Response and outcomes of cardiac resynchronization therapy in patients with renal dysfunction.

Authors:  Rita Ilhão Moreira; Pedro Silva Cunha; Pedro Rio; Manuel Nogueira da Silva; Luísa Moura Branco; Ana Galrinho; Joana Feliciano; Rui Soares; Rui Cruz Ferreira; Mário Martins Oliveira
Journal:  J Interv Card Electrophysiol       Date:  2018-02-19       Impact factor: 1.900

Review 7.  Role of Atrio-Ventricular Junction Ablation in Symptomatic Atrial Fibrillation for Optimization of Cardiac Resynchronization Therapy.

Authors:  Paul J Garabelli; Stavros Stavrakis
Journal:  J Atr Fibrillation       Date:  2013-04-06

8.  Non-contrast cardiac resynchronization therapy implantation is feasible in case of renal insufficiency.

Authors:  Sok-Sithikun Bun; Decebal Gabriel Latcu; Abdelkarim Errahmouni; Nadir Saoudi
Journal:  J Interv Card Electrophysiol       Date:  2015-06-17       Impact factor: 1.900

9.  Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease.

Authors:  Usama A Daimee; Yitschak Biton; Arthur J Moss; Wojciech Zareba; David Cannom; Helmut Klein; Scott Solomon; Martin H Ruwald; Scott McNitt; Bronislava Polonsky; Paul J Wang; Ilan Goldenberg; Valentina Kutyifa
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-09-15       Impact factor: 1.468

10.  Serum phosphate levels reflect responses to cardiac resynchronization therapy in chronic heart failure patients.

Authors:  Yoshiyuki Kamiyama; Hitoshi Suzuki; Shinya Yamada; Takashi Kaneshiro; Yasuchika Takeishi
Journal:  J Arrhythm       Date:  2014-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.